RIP2-kinase-inhibitor-1 - RIP kinase 抑制劑 - 生命科學試劑 - MedChemExpress_第1頁
RIP2-kinase-inhibitor-1 - RIP kinase 抑制劑 - 生命科學試劑 - MedChemExpress_第2頁
RIP2-kinase-inhibitor-1 - RIP kinase 抑制劑 - 生命科學試劑 - MedChemExpress_第3頁
全文預覽已結束

下載本文檔

版權說明:本文檔由用戶提供并上傳,收益歸屬內容提供方,若內容存在侵權,請進行舉報或認領

文檔簡介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemERIP2 kinase inhibitor 1Cat. No.: HY-19764CAS No.: 1423186-80-4分式: CHNOS分量: 458.55作靶點: RIP kinase作通路: Apoptosis儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數據體外實驗 DMSO : 32 mg/mL (69.79 mM)* means solu

2、ble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 2.1808 mL 10.9039 mL 21.8079 mL5 mM 0.4362 mL 2.1808 mL 4.3616 mL10 mM 0.2181 mL 1.0904 mL 2.1808 mL請根據產品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 RIP2 kinase inhibitor 1種受體相互作蛋-2 (RIP2) 激酶抑制劑,詳細信息請參考專

3、利 WO/2014043446A1 中的化合物 example 1。IC50 & Target RIP2 Kinase 1體外研究RIP2 kinase inhibitor 1 is a novel prodrug of a quinazolyl amine that inhibits RIP2 kinase. Receptor1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEinteracting protein-2 (RIP2) kinase, which is also referred to as CARD3, RICK, CARDIAK

4、, or RIPK2, is a TKLfamily serine/threonine protein kinase involved in innate immune signaling. RIP2 kinase is composed of an N-terminal kinase domain and a C-terminal caspase-recruitment domain (CARD) linked via an intermediate (IM)region. The CARD domain of RIP2 kinase mediates interaction with ot

5、her CARD-containing proteins, such asNODI and NOD2. NODI and NOD2 are cytoplasmic receptors which play a key role in innate immunesurveillance. They recognize both gram positive and gram negative bacterial pathogens and are activated byspecific peptidoglycan motifs, diaminopimelic acid (i.e., DAP) a

6、nd muramyl dipeptide 1.PROTOCOLAnimal Rats 1Administration 1 Rats are orally pre-dosed with RIP2 kinase inhibitor 1, at a dose of 2 mg/kg (8 rats) and with Prednisolone (8rats, used as a positive control), followed by dosing with L18-MDP (50 g/rat) 0.25 h/min after pre-dosing.Combined cytokine level

7、s (IL8, TNFa, IL6 and IL-) in whole blood samples taken from the rats in this studyare measured using an antibody based detection. The combined cytokine response is calculated as theaveraged response for the 4 cytokines measured relative to the response observed in the vehicle-treatedmice, and are d

8、epicted as the meanstandard error of the mean (n=8 rats/group).MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Linda N. Casillas, et al. Prodrugs of amino quinazoline kinase inhibitor. PCT Int. Appl. (2014), WO 2014043446 A1 20140320.McePdfHeightCaution: Product has not been fully validated for medical applications

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯系上傳者。文件的所有權益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網頁內容里面會有圖紙預覽,若沒有圖紙預覽就沒有圖紙。
  • 4. 未經權益所有人同意不得將文件中的內容挪作商業或盈利用途。
  • 5. 人人文庫網僅提供信息存儲空間,僅對用戶上傳內容的表現方式做保護處理,對用戶上傳分享的文檔內容本身不做任何修改或編輯,并不能對任何下載內容負責。
  • 6. 下載文件中如有侵權或不適當內容,請與我們聯系,我們立即糾正。
  • 7. 本站不保證下載資源的準確性、安全性和完整性, 同時也不承擔用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論